You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
Mission Bio will use a recent $70 million funding round to develop quality control assays using its Tapestri single-cell analysis platform.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.
Researchers from South Korea used 10x Genomics' scRNA-seq platform to also find type I IFN-driven inflammatory features in patients with severe influenza.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.